[COVID-19: Still a place for tocilizumab?].
作者信息
Richier Q, Plaçais L, Lacombe K, Hermine O
机构信息
Service de maladies infectieuses, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
Service d'hématologie, hôpital Necker, Assistance publique des Hôpitaux de Paris, Paris, France; Sorbonne université, Paris, France.
出版信息
Rev Med Interne. 2021 Feb;42(2):73-78. doi: 10.1016/j.revmed.2020.11.016. Epub 2020 Nov 27.
Abstract
摘要
相似文献
1
[COVID-19: Still a place for tocilizumab?].[新型冠状病毒肺炎：托珠单抗仍有一席之地？]
Rev Med Interne. 2021 Feb;42(2):73-78. doi: 10.1016/j.revmed.2020.11.016. Epub 2020 Nov 27.
2
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
3
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
4
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.COVID-19 病毒感染管理的 COVIRL002 试验-托珠单抗：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 3;21(1):758. doi: 10.1186/s13063-020-04680-w.
5
Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date.托珠单抗治疗非重症 COVID-19 肺炎：综述迄今为止的作用机制和临床证据。
Expert Rev Clin Pharmacol. 2021 Oct;14(10):1279-1287. doi: 10.1080/17512433.2021.1949286. Epub 2021 Jul 26.
6
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
7
Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.托珠单抗治疗重症 COVID-19 肺炎：5 例澳大利亚患者的病例系列
Int J Rheum Dis. 2020 Aug;23(8):1030-1039. doi: 10.1111/1756-185X.13913.
8
Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.与白细胞介素-6升高相关的血管微血栓形成。在接受托珠单抗治疗的COVID-19患者中出现的严重急性呼吸窘迫综合征。
Adv Respir Med. 2020;88(5):468-469. doi: 10.5603/ARM.a2020.0123.
9
Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.托珠单抗治疗 COVID-19 患者：新型疾病推荐药物。
Int Immunopharmacol. 2020 Dec;89(Pt A):107018. doi: 10.1016/j.intimp.2020.107018. Epub 2020 Sep 16.
10
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析，首次更新。
Clin Microbiol Infect. 2021 Aug;27(8):1076-1082. doi: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27.
引用本文的文献
1
Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.抗新冠病毒治疗策略的进展以及针对新出现的新冠病毒变种的药物设计前景。
Comput Struct Biotechnol J. 2022;20:824-837. doi: 10.1016/j.csbj.2022.01.026. Epub 2022 Jan 31.
2
Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis.托珠单抗治疗 COVID-19 患者的临床结局预测因素：一项单中心回顾性分析。
PLoS One. 2022 Jan 26;17(1):e0262908. doi: 10.1371/journal.pone.0262908. eCollection 2022.
本文引用的文献
1
Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis.评估无症状新冠病毒感染的程度及其社区传播潜力：系统评价与荟萃分析。
J Assoc Med Microbiol Infect Dis Can. 2020 Dec 31;5(4):223-234. doi: 10.3138/jammi-2020-0030. eCollection 2020 Dec.
2
Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.托珠单抗在新型冠状病毒肺炎中的应用：当前证据的系统评价与荟萃分析
Cureus. 2020 Oct 9;12(10):e10869. doi: 10.7759/cureus.10869.
3
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5.
4
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
5
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
6
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
7
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.COVID-19 重症患者早期使用托珠单抗治疗与死亡率的关联。
JAMA Intern Med. 2021 Jan 1;181(1):41-51. doi: 10.1001/jamainternmed.2020.6252.
8
Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia.重新评估托珠单抗在新冠肺炎肺炎中作用的时机
JAMA Intern Med. 2021 Jan 1;181(1):12-15. doi: 10.1001/jamainternmed.2020.6557.
9
Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.比较免疫调节疗法治疗 2019 年冠状病毒病细胞因子风暴的生存分析。
Chest. 2021 Mar;159(3):933-948. doi: 10.1016/j.chest.2020.09.275. Epub 2020 Oct 17.
10
Preemptive interleukin-6 blockade in patients with COVID-19.COVID-19 患者的预防性白细胞介素 6 阻断。
Sci Rep. 2020 Oct 8;10(1):16826. doi: 10.1038/s41598-020-74001-3.
Zotero 插件